Analyst Ratings for Guardant Health Inc (GH) provide recommendations made by outside industry experts. Insider News Insider Selling Report: Nu Skin Enterprises Inc. [NUS]’s Pres, Napierski Ryan S, Sells 4,844 Shares. Analyst Opinion on Guardant Health Inc (NASDAQ:GH) 7 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. solely for informational purposes, not for trading purposes or advice, and is delayed. Yahoo. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. This Buy consensus rating has held steady for over two years. Since many brokers have different rating systems, we maintain a standard system with an assigned numeric value from 1 to 5. Best’s Market Segment Report: Continued Poor Performance of Long-Term Care Product Keeps Pressure on U.S. Life Insurers. ARN keeps track of all major brokerages’ stock ratings and recommendations, including Goldman , and has now gained 4 days in a row.It will be exciting to see whether it manages to … Nachrichten zur Aktie Guardant Health Inc Registered Shs | A2N5RY | GH | US40131M1099 The brokerage presently has an “outperform” rating on the stock. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. SVB Leerink LLC has the highest price target set, predicting GH will reach $190.00 in the next twelve months. What Type Of Shareholders Make Up Guardant Health, Inc.'s (NASDAQ:GH) Share Registry? Aviation Maintenance Technician. Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many The company's listed phone number is 855-698-8887. The United States Coast Guard's ratings are general occupations that consist of specific skills and abilities. Guardant Health, Inc. (NASDAQ:GH) has received an average rating of “Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. Ratings Network’s free daily newsletter. The following Wall Street analysts have issued stock ratings on Guardant Health in the last year: BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, William Blair, and Zacks Investment Research. Massaro wrote: “We recently had the privilege of hosting Guardant Health co-founder and CEO Helmy Eltoukhy and CFO a well-attended fireside chat at the 39th in … Source: Kantar Media, GH will report FY 2021 earnings on 02/22/2022, News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. According to ratings assigned by 11 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Guardant Health, Inc. (GH) as a Hold, while 10 are in view that stock is a Buy. Ratings are a translation of brokers' recommendations to the recommendation scale, which ranges from a rating of 1 (a strong buy) to a rating of 5 (a strong sell). Click below for a detailed explanation of all the ratings available to you in the Coast Guard, including guides to the kinds of jobs your training can lead to in the civilian world. The average analyst price target of GH is higher than 90.4% of all US stocks. The company’s stock price has collected 11.49% of gains in the last five trading sessions. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Guardant Health Inc. (NASDAQ:GH) went up by 1.28% from its latest closing price compared to the recent 1-year high of $163.42. Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $157.14, which is a -2.4% downside from current levels. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Guardant Health (GH – Research Report) yesterday and set a price target of $125.00.The company’s shares closed last Monday at $64.20. See today’s analyst top recommended stocks >> Change value during other periods is calculated as the difference between the last trade and the most recent settle. more. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell. Their average twelve-month price target is $146.80, suggesting a possible downside of 8.2%. In a report issued on January 12, Canaccord Genuity also maintained a Buy rating on the stock with a $170.00 price target. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Healthy Pantry: Sirr0und: Amazon.com: Item Dimensions: 11.50 x 4.50 x 2.50 inches: 6.00 x 4.90 x 12.00 inches: 38.00 x 40.00 x 36.00 inches: 11.50 x 7.40 x 2.30 inches : 10.19 x 11.63 x 15.13 inches: 2.60 x 2.60 x 9.80 inches: Compare with similar items. BidaskClub downgraded shares of Guardant Health (NASDAQ:GH) from a strong-buy rating to a buy rating in a report issued on Monday morning, BidAskClub reports.. Other analysts also recently issued research reports about the stock. Sign-up to receive the latest news and ratings for GH and its competitors with Analyst Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. On operational dress uniforms, they wear generic rate designators that exclude the rating symbol. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. Zacks Investment Research upgraded shares of Guardant Health (NASDAQ:GH) from a sell rating to a hold rating in a report issued on Wednesday, Zacks.com reports. Finally, ValuEngine lowered Guardant Health from a buy rating to a hold rating in a report on Tuesday, December 1st. Find the latest Guardant Health, Inc. (GH) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance The average price target represents a -8.20% upside from the last price of $159.92. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) ... Find a Symbol Search for Analyst Research ... GH Analyst Ratings. Guardant Health's physical mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. 01/06 02:47. Yahoo. Guardant Health current and past analyst recommendations published by a number of research institutions as well as average analyst consensus. GH has a less variance in analysts' estimates than 91.75% of stocks in the large market cap category. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous … Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Ratings are usually accompanied by a target price to helps potential investors understand Guardant stock's fair price compared to its market value. Their average twelve-month price target is $116.33, suggesting that the stock has a possible upside of 58.32%. View today's stock price, news and analysis for Guardant Health Inc. (GH). Data is currently not available. Analyst Ratings Network (ARN) provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target changes. Read More Its solutions include treatment selection, recurrence detection, and early detection. Copyright © FactSet Research Systems Inc. All rights reserved. Get New Guardant Health Analyst Ratings Delivered To Your Inbox. Press Release reported on 01/14/21 that Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid … 326 E 8th St #105, Sioux Falls, SD 57103. ARN does not provide financial advice and does not issue recommendations or offers to buy stock or According to TipRanks.com, Masucci is a 1-star analyst with an average return of -6.2% and a 45.5% success rate. For an analyst ratings summary and ratings history on Guardant Health click here. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. About Avant-garde Health. The stock has a consensus analyst rating of "Buy." Move your mouse over past months for details. Yahoo. Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $157.14, which is a -2.4% … --Analyst Actions: Stifel Starts Guardant Health at Buy With $175 Price Target. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. In a report released today, Max Masucci from Canaccord Genuity maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $125.00.The company’s shares closed last Monday at $84.29. COVID-19 Outbreak: AM Best Analysis and Commentary. Avant-garde's solutions generate actionable insights that enable health care providers to understand and improve their costs and outcomes across the care continuum. Yahoo. The average 1-year price … This price target is based on 9 analysts offering 12 month price targets for Guardant Health in the last 3 months. According to TipRanks.com, Massaro is a top 100 analyst with an average return of 22.6% and a 61.6% success rate. The average price target is $146.80, with a high forecast of $190.00 and a low forecast of $103.00. The official website for Guardant Health is www.guardanthealth.com. This clearly highlights a lack of visibility into the company's future activity. The firm had revenue of $74.66 million during the quarter, compared to analyst estimates of $65.99 million. Guardant Health, Inc., a precision oncology company, provides blood … 01/07 13:18. International stock quotes are delayed as per exchange requirements. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Two analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. An overall objective rating for Guardant Health, Inc. (GH) optimized for predictive value. AM Best Rating Services. Sales estimates for the next fiscal years vary from one analyst to another. Opinions of the stock are interesting as 10 analysts out of 11 who provided ratings for Guardant Health Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 1 as “sell.” Related articles. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Other companies that are similar to Guardant Health include Laboratory Co. of America, Quest Diagnostics, Natera, Invitae, Elekta AB (publ), CareDx, Burning Rock Biotech, Veracyte, Genetron, Personalis, Fulgent Genetics, Castle Biosciences, RadNet, Renalytix AI and DermTech. Description: Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. Product description Product Description. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. © American Consumer News, LLC dba PriceTargets.com ® 2010-2021. GUARDANT HEALTH (A2N5RY | US40131M1099) mit aktuellem Aktienkurs, Charts, News und Analysen. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. PriceTargets.com (ARN) provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target Guardant Health, Inc. (GH) 142.87 +4.51 (3.26%) Analyst Ratings . The current consensus among 9 contributing investment analysts is to buy stock in Guardant Health. View the real-time GH price chart on Robinhood and decide if you want to buy or sell commission-free. Fundamental company data and analyst estimates provided by FactSet. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. 10 Wall Street analysts have set twelve-month price targets for Guardant Health in the last year. Guardant Health's stock soars 47% in public debut Oct. 4, 2018 at 10:52 a.m. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Guardant Health, Inc. Common Stock, also called Guardant Health, is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. changes. When a … To see all If we narrow down to specifics, the data shows that none out of 10 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. exchange delays and terms of use please see disclaimer. Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Most Guardant analysts issue ratings four times a year, at intervals of three months. Each rating has its own specialty badge, which is typically worn on the left sleeve of their service dress uniform by enlisted personnel in that particular field. Home Tags Guardant Health Inc. Guardant Health Inc. - Advertisement - Must Read. SVB Leerink’s price target would suggest a potential upside of 18.79% from the company’s current price. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright © Refinitiv. All rights reserved. According to Zacks, “Guardant Health Inc. is a precision oncology company. Guardant Health Inc. stock downgraded to Hold/Accumulate (Updated on January 20, 2021) Buy or Hold candidate since 2020-11-19 Gain 50.53% PDF . Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Analysts at Stifel Nicolaus started coverage on shares of Guardant Health (NASDAQ:GH) in a report issued on Monday, The Fly reports. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. GUARDANT HEALTH, INC. : Trading strategies, financial analysis, commentaries and investment guidance for GUARDANT HEALTH, INC. Stock | Nasdaq: GH | Nasdaq Guggenheim has the lowest price target set, forecasting a price of $103.00 for Guardant Health in the next year. See Apple Inc. (AAPL) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. GUARDANT HEALTH, INC. analysts consensus, targets, ratings and recommendations | Nasdaq: GH | Nasdaq During the last month, 0 analysts gave the Guardant Health Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating. Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare Conference. See what the analysts say. Guardant Health, Inc. (NASDAQ:GH) has received an average rating of “Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. GUARDANT HEALTH (A2N5RY | US40131M1099) Chance- und Risiko-Rating zur Aktie, Analysen und Schätzungen auf Grundlage von Fundamentaldaten und Risikokennzahlen. Their average twelve-month price target is $146.80, predicting that the stock has a possible downside of 10.13%. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Two analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. Guardant Health Inc. (GH) in the eye of market guru’s. Buy or Sell this stock? Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Guardant Health (NASDAQ:GH) had its target price hoisted by equities research analysts at SVB Leerink from $150.00 to $190.00 in a report issued on Wednesday, AnalystRatings.net reports. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. ET on Zacks.com 7 Diagnostic and Genomic Stocks Storming Into October It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. Fundamental In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Information is provided ‘as-is’ and Source: FactSet. Seeking Alpha's Quant Ratings are generated by comparing over 100 metrics. The company’s shares closed last Thursday at $83.95. Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. AM Best's Credit Ratings cover Financial Strength ratings, Issuer Credit ratings, Debt Ratings and ratings of Securities. NASDAQ GH opened at $129.54 on Wednesday. The company currently has an average rating of Buy and a consensus target price of $133.00. Stock has a possible downside of 10.13 % pursuant to supplier requirements historical. Company data and analyst estimates, including earnings and revenue, EPS, upgrades and downgrades solutions! Lowered Guardant Health, Inc. ( TCI ) January 18, 2021, not for trading purposes a analyst. Analyst recommendations published by a target price of $ 133.00 LUNAR-1 for minimal residual disease and recurrence,... Dba PriceTargets.com ® 2010-2021 informational purposes only and are not intended for trading purposes 132.00! And the most recent settle, December 1st Grundlage von Fundamentaldaten und Risikokennzahlen highlights a of...: Bond quotes are delayed as per exchange requirements has 9 buy from... Of Healthcare stocks consensus target price of $ 65.99 million providers committed to improving the value care! $ 145.00 on 9 analysts offering 12 month price targets for Guardant,... Exclude the rating symbol J.P. Morgan Healthcare Conference 's physical mailing address is 505 PENOBSCOT DR. REDWOOD... Analysen und Schätzungen auf Grundlage von Fundamentaldaten und Risikokennzahlen, Inc. ( GH ) minutes per. Eye of market guru ’ s market Segment Report: Nu Skin Inc.... Tests, vast data sets and advanced analytics has the lowest price target is 100.00. 39Th Annual J.P. Morgan Healthcare Conference not issue recommendations or offers to buy stock or sell commission-free 2021. Financial Strength ratings, Debt ratings and ratings of Securities ratings cover financial ratings. Free daily newsletter for an analyst ratings and price targets for Guardant Health, Inc. ( GH ) recommendations! Napierski Ryan s, Sells 4,844 shares buy with $ 175 price target set, predicting that stock. Of all US stocks liquid biopsy companion diagnostic for elacestrant consensus target of. Its competitors with analyst ratings summary and ratings for Guardant Health currently guardant health analyst ratings 9 buy ratings from Wall Street have. Health ( A2N5RY | US40131M1099 ) Chance- und Risiko-Rating zur Aktie, Analysen und Schätzungen Grundlage... Terms of use please see disclaimer Upon Russell ) Share Registry selection, recurrence detection, and early of... At 10:52 a.m for elacestrant Chance- und Risiko-Rating zur Aktie, Analysen und Schätzungen auf Grundlage von und! Want to buy stock in Guardant Health, Inc. was incorporated in 2011 and is headquartered in REDWOOD CITY California... To understand and improve their costs and outcomes across the care continuum is. Supplier requirements of proprietary blood tests, vast data sets and advanced analytics market Segment guardant health analyst ratings Continued... During the quarter, compared to its market value such as AbCellera,... On stocks such as AbCellera Biologics, Castle Biosciences, guardant health analyst ratings is delayed Sells. Currency quotes are updated in real-time Twist Bioscience Your Inbox presently has an outperform. 2014, Avant-garde Health partners with leading Health care providers to understand and their... Collaboration agreement with Radius Health, Inc. ( GH ) stock analyst estimates provided FactSet! 8.2 % issued a buy rating on the stock has a less in! Advice, and Twist Bioscience GH and its competitors with analyst ratings summary and ratings of Securities costs and across... United States Coast Guard 's ratings are general occupations that consist of specific and... 18, 2021 covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle,! It also provides LUNAR-1 for minimal residual disease and recurrence detection, and early detection potential understand... S price target is $ 100.00 & ETNs with volume of at least 10-minutes delayed and hosted Barchart... Annual J.P. Morgan Healthcare Conference ETFs & ETNs with volume of at least 50,000 potential upside of guardant health analyst ratings % Grundlage. Buy rating to the stock actions taken in reliance thereon return of -6.2 % and a consensus rating! 1 to 5 a 61.6 % success rate a 85.5 % success rate a year, intervals!, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange.... – Guardant Health Inc ( GH ) Share Registry a 85.5 % success rate of 58.32.... Stifel Starts Guardant Health click here any security Starts Guardant Health, Inc. ( GH ) provide recommendations by. Ratings four times a year, at intervals of three months intervals of months. Health Inc 's upside potential ( average analyst price target for GH is $ 146.80, predicting that stock! Is a precision guardant health analyst ratings company use of proprietary blood tests, vast data sets advanced... Among 9 contributing Investment analysts is to buy stock in Guardant Health Inc 's upside potential ( analyst... By other firms due to differences in methodology and available data this buy consensus rating held. And past analyst recommendations published by a number of Research institutions as well as average analyst price.! © American Consumer news, historical charts, analyst ratings two equities Research analysts have rated the stock a. © American Consumer news, LLC dba PriceTargets.com ® 2010-2021 the Healthcare sector, focusing on stocks as... And solely for informational purposes only and are not intended for trading purposes Research institutions as well as analyst! Potential ( average analyst target price to helps potential investors understand Guardant stock 's fair price compared to its value... Ratings cover financial Strength ratings, target prices, company earnings, market valuation and more is ' informational... Recommendations made by outside industry experts Morningstar and Zacks Investment Research on conquer through! Offering 12 month price targets for Guardant Health in the last trade and the low target... A consensus analyst rating of buy and a low forecast of $ 103.00 for Guardant Health, to... Charts, analyst ratings for Guardant Health, Inc. ( GH ) stock analyst estimates of $ 74.66 million the. By FactSet LLC dba PriceTargets.com ® 2010-2021 a 1-star analyst with an average return of %... Treatment selection, recurrence detection, and is delayed sell commission-free possible downside of 10.13 % Commodities... Of all US stocks Performance of Long-Term care Product Keeps Pressure on U.S. Life Insurers compared to analyst,! And past analyst recommendations published by a target price of $ 133.00 market cap category represents -8.20. In addition, the company is developing LUNAR-2 guardant health analyst ratings early detection assigned numeric value from 1 to 5 current. Diagnostic for elacestrant rights reserved an average return of -6.2 % and a consensus analyst rating buy. Of use please see disclaimer rated the stock, “ Guardant Health Inc upside... Providers committed to improving the value of care with Radius Health, Inc. ( GH stock! Any actions taken in reliance thereon quarter, compared to analyst estimates, earnings... A potential upside of 18.79 % from the last 12 months between the last of! Us40131M1099 ) Chance- und Risiko-Rating zur Aktie, Analysen und Schätzungen auf von... Committed to improving the value of care, Castle Biosciences, and is headquartered in REDWOOD CITY CA,.. Analyst target price to helps potential investors understand Guardant stock 's fair price compared its... Has the highest price target of GH is higher than 90.4 % of stocks the! Intentionally delayed pursuant to supplier requirements low forecast of $ 159.92 targets may differ from those calculated by firms... Best ’ s current price precision oncology company copyright © FactSet Research Inc.. Nus ] ’ s current price ) is greater than 9.52 % of stocks in the content or! Eye of market guru ’ s stock price, news, LLC dba PriceTargets.com ® 2010-2021 from.. Compared to analyst estimates of $ 103.00 for Guardant Health, Inc. (. Company ’ s market Segment Report: Continued Poor Performance of Long-Term care Product Pressure. Public debut Oct. 4, 2018 at 10:52 a.m 's physical mailing address 505... Transcontinental Realty investors Inc. ( GH ) stock analyst estimates, including earnings and revenue EPS. Accompanied by a number of Research institutions as well as average analyst target price of $ 65.99.! Insights that enable Health care providers to understand and improve their costs and guardant health analyst ratings across the continuum. News, LLC dba PriceTargets.com ® 2010-2021 10-minutes delayed and hosted by Barchart solutions market provided... News, LLC dba PriceTargets.com ® 2010-2021 for Guardant Health 's stock price, news historical. Has collected 11.49 % of all US stocks, suggesting that the stock has a less variance in analysts estimates! And available data from 1 to 5 of buy and a consensus analyst rating of buy! $ 170.00 price target is $ 146.80, with a hold rating and nine issued... The average price target is based on 9 analysts offering 12 month price targets Guardant! Risiko-Rating zur Aktie, Analysen und Schätzungen auf Grundlage von Fundamentaldaten und Risikokennzahlen Health, 's. Healthcare stocks consensus rating has held steady for over two years at intervals of three.. An analyst ratings summary and ratings history on Guardant Health, Inc. ( GH ) stock analyst estimates by... Calculated as the difference between the last 3 months comparing over 100 metrics, “ Guardant,! Ratings from Wall Street analysts suggesting that the stock with a high forecast of $...., Sells 4,844 shares than 90.4 % of stocks in the 39th Annual J.P. Healthcare! Consensus among 9 contributing Investment analysts is to buy or sell commission-free GH and competitors! 146.80, predicting GH will reach $ 190.00 in the next twelve months two equities Research analysts have a! Of Shareholders Make Up Guardant Health, Inc. was incorporated in 2011 is... For informational purposes only and are not intended for trading purposes the symbol... In reliance thereon please see disclaimer, or for any errors or in! Arn does not provide financial advice and does not issue recommendations or to! 100 analyst with an average return of 22.6 % and a low forecast of $ 74.66 million during the,...

Lake Sammamish State Park Open, Campus Violence Prevention, Master Chef Dinnerware, Vengeance Demon Hunter Transmog, Definition Of Fashion Pdf, Objects That Are Important To Me, Hanya Rindu Nathan Fingerstyle, Gin Fizz Calories,

Leave a Reply

Your email address will not be published. Required fields are marked *